{'fraction_non_alphanumeric': 0.045754956786985254, 'fraction_numerical': 0.03202846975088968, 'mean_word_length': 5.368932038834951, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A1814 Comparative Effects of Valsartan plus Either Cilnidipine or Hydrochlorothiazide on Nocturnal Home Blood Pressure in Patients with Morning Hypertension

Objectives: We tested our hypothesis that a valsartan/cilnidipine combination would reduce and optimize nocturnal home systolic blood pressure (HSBP), assessed by information and communication technology (ICT)-based home BP monitoring device, compared to a valsartan/hydrochlorothiazide (HCTZ) combination in patients with morning hypertension, defined as morning SBP ≥135 mmHg or diastolic BP ≥85 mmHg. Methods: This study was a 8-week prospective, multicenter, randomized, open-label clinical trial conducted in Japan. Patients were asked to measure nocturnal HSBP over 3 nights prior to the study randomization and the end of treatment. Eligible patients were randomly allocated to either the valsartan/cilnidipine (80/10 mg) or valsartan/HCTZ (80/12.5 mg) combination groups. Results: Forty-eight patients (mean 69.6 years, 39.6 % male) and fifty patients (mean 67.0 years, 46.0 % male) were assessed in the valsartan/cilnidipine group and the valsartan/HCTZ group, and their baseline nocturnal HSBP were 124.3 ± 15.6 and 125.8 ± 15.2 mmHg, respectively (p = 0.597). Although nocturnal HSBP was significantly reduced from baseline in both treatment groups, the valsartan/HCTZ group significantly reduced nocturnal HSBP compared to the valsartan/cilnidipine group (−5.0 vs. − 10.0 mmHg, p = 0.035). However, the significant interaction between treatment groups concerning the baseline nocturnal HSBP level and the change in nocturnal HSBP was observed (p = 0.047), which indicated that the valsartan/cilnidipine combination did not reduce nocturnal HSBP in patients with already controlled, while it could reduce nocturnal HSBP in patients with uncontrolled. Conclusion: Valsartan/cilnidipine combination could reduce and optimize nocturnal HSBP levels more effectively than the valsartan/HCTZ combination.